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Disruption of circadian clock enhances the risk of metabolic syndrome, obesity, and type
2 diabetes. Circadian clocks rely on a highly regulated network of transcriptional and trans-
lational loops that drive clock-controlled gene expression. Among these transcribed clock
genes are cryptochrome (CRY) family members, which comprise Cry1 and Cry2. While
the metabolic effects of deletion of several core components of the clock gene machinery
have been well characterized, those of selective inactivation of Cry1 or Cry2 genes have
not been described. In this study, we demonstrate that ablation of Cry1, but not Cry2, pre-
vents high-fat diet (HFD)-induced obesity in mice. Despite similar caloric intake, Cry1−/−
mice on HFD gained markedly less weight (−18%) at the end of the 16-week experiment
and displayed reduced fat accumulation compared to wild-type (WT) littermates (−61%),
suggesting increased energy expenditure. Analysis of serum lipid and glucose profiles
showed no difference between Cry1−/− and WT mice. Both Cry1−/− and Cry2−/− mice are
indistinguishable from WT controls in body weight, fat and protein contents, and food con-
sumption when they are allowed unlimited access to a standard rodent diet. We conclude
that although CRY signaling may not be essential for the maintenance of energy home-
ostasis under steady-state nutritional conditions, Cry1 may play a role in readjusting energy
balance under changing nutritional circumstances. These studies reinforce the important
role of circadian clock genes in energy homeostasis and suggest that Cry1 is a plausible
target for anti-obesity therapy.
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INTRODUCTION
The biological clock is an extensive molecular network that pro-
vides circadian time-keeping, controlling and maintaining daily
rhythms of many behavioral and physiological processes. In mam-
mals, it comprises a complex circuitry of transcriptional and
translational regulatory feedback loops, including the core tran-
scriptional activators CLOCK and BMAL1, which activate expres-
sion of three Period (Per1–3) and two cryptochrome (Cry1 and
Cry2) genes (1). These latter products are part of the negative
regulatory arm of the circadian clock system as their rhythmical
accumulation leads to the formation of a repressor complex that
interacts with CLOCK and BMAL1 to inhibit their own transcrip-
tion. Mammalian clocks not only reside in the suprachiasmatic
nucleus (SCN), in which the clock is determined by light signals
through the retinohypothalamic tract, but they have been iden-
tified in a wide array of peripheral organs including heart, lung,
kidney, liver, and pancreas, where their timing is set by metabolic
cues (2–4).
Perturbation of endogenous circadian rhythms driven by clock
gene mutations or disruptive lifestyles has been shown to give rise
to various pathophysiological manifestations (5–7). This associ-
ation is particularly strong with respect to cancer and metabolic
disease. For example, sleep disturbances or long-term shift work
has been shown to increase the risk of developing type 2 diabetes
(8–11). Moreover, polymorphisms of the core clock genes Clock
and Bmal1 are associated with obesity and type 2 diabetes (12,
13). Genetic mouse models also show that mutation in the genes
encoding core clock transcription factors resulted in metabolic
disturbances [for a review, see Ref. (6)]. This is best illustrated by
mice deficient in Clock or Bmal1, which display impaired glucose
tolerance and reduced insulin secretion (14). Moreover, disrup-
tion of Per2 and Per1–3 in mice results in increased vulnerability
to high-fat-induced obesity and/or food intake (15). However, the
situation is far from being clear with respect to these repressor
clock genes as other studies demonstrated that mutation in Per
1, Per2, and Per1–3 resulted in reduced food intake and/or body
weight in mice (16, 17). It was argued that the PER proteins may
not be the best representatives of the negative regulatory arm
of the molecular clock because they do not directly inhibit the
core clock proteins, unlike cryptochromes (CRY) (18). Although
there are several studies on the consequences of Cry1, Cry2, and
Cry1/2 deletion, mainly on behavioral and molecular rhythmicity,
only one has investigated the effects of Cry1−/−Cry2−/− double
mutation on metabolism (18). These authors showed that defi-
ciency in CRY resulted in increased susceptibility to diet-induced
obesity as a consequence of increased insulin secretion and lipid
storage.
To explore further the role of CRY on metabolism, the current
study was undertaken to assess the effects of single deletion of
either Cry1 or Cry2 on high-fat-induced obesity.
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MATERIALS AND METHODS
ANIMALS
In all experiments mice were housed individually at a constant
temperature of 21± 1°C and humidity (50± 10%) on a reverse
light–dark cycle under a 12:12 light/dark cycle (light on at 7:00
a.m.). Six- to 10-week-old male Cry1−/−, Cry2−/− mice, and
their respective wild-type (WT) counterparts were obtained from
The Jackson Laboratories. They were fed ad libitum either under
standard-mouse diet (STD) containing 3.7 kcal/g (A04, UAR; 15%
fat, 12% protein, 73% carbohydrate) or under a high-fat diet
(HFD) of 4.7 kcal/g energy density (D12451, Research Diet; 45%
fat, 22% protein, 33% carbohydrate). Genotypes were determined
by PCR of tail DNA. Animals were age-matched WT controls
(Cry1+/+ or Cry2+/+) and homozygous (Cry1−/− or Cry2−/−)
offsprings produced by backcrossing onto C57BL/6J background.
All experimental procedures described herein were approved by
the Animal Care and Use Committee of Sanofi or the Institu-
tional Animal Care. Our animal facilities and animal care and
use programs are in accordance with French legislation which
implemented the European directive 86/609/EEC.
EXPERIMENTAL PROCEDURE
In the first experiment, 8- to 10-week-old Cry1−/− mice (n= 9–
10) were compared to WT animals (Cry1+/+) in two feeding
paradigms for 16 weeks: (a) on a STD laboratory regimen, and (b)
on a HFD regimen. In the second experiment, 6- to 9-week-old
Cry2−/− mice (n= 12) were compared to their WT counter-
parts (Cry2+/+) (n= 15) in the two same feeding paradigms for
10 weeks. We have used a shorter time period in the Cry2 study
because body weight evolution was not different between groups
after 2 months of experiment, regardless the genotype and the
regimen.
BODY WEIGHT, BODY COMPOSITION, AND ENERGY INTAKE
Body weight changes were recorded once a week. Body com-
position (fat and protein contents) was assessed in Cry1+/+
and Cry1−/− mice fed a HFD at the end of the experi-
ment using the total body electrical conductivity technique
(TOBEC system, EMSCAN 3000). This instrument measures
total body electrical conductivity of small animals in a non-
invasive manner (19). Body composition expressed as percentage
protein mass or fat mass was obtained mathematically: protein
(a): [0.816662+ 0.002615×TOBEC+ 0.046624× body weight
(BW)− 0.000066×BW×TOBEC]2; fat (b): (−0.732127−
0.008899×TOBEC+ 0.198538×BW)2. Because we observed a
different evolution in weight gain in Cry1−/− mice compared to
their WT littermates under a HFD, energy intake was assessed
weekly between weeks 12 and 16 in these groups.
Serum analysis
Plasma levels of glucose, triglycerides (TGs), free fatty acids (FFAs),
and free cholesterol were determined in Cry1+/+ and Cry1−/−
mice at the end of the 16-week HFD regimen in fed animals.
Animals were sacrificed, blood was collected into EDTA-rinsed
capillaries, and plasma was immediately prepared. Free choles-
terol, TGs, and glucose were determined using enzymatic kits from
Sigma. Plasma FFA levels were measured using the Wako kit (Wako
Chemicals, Richmond, VA, USA).
STATISTICAL ANALYSES
All data are shown as mean± SEM. ANOVA and post hoc analyses
were performed using SAS v.12 software. For body weight changes,
statistical analysis was performed using a two-way ANOVA (factor
strain× diet, with repeated measures on factor week). For food
intake, a two-way ANOVA (factor strain or diet, with repeated
measures on factor week) was performed. Finally, for body com-
position and serum analyses, a one-way ANOVA was used followed
by post hoc comparisons with the Dunnett’s test. P-values <0.05
were considered statistically significant.
RESULTS
SUSCEPTIBILITY OF CRY1−/− MICE TO HIGH-FAT-INDUCED OBESITY
Growth and body temperature
Cry1-deficient mice displayed the same fur quality than WT ani-
mals and they grew normally as assessed by naso-anal length,
similar in both groups at 26-week of age (Cry1+/+= 9.7± 0.1 cm;
Cry1−/−= 9.3± 0.2 cm). In addition, there were no signifi-
cant differences detectable in the body temperature between
the two genotypes (Cry1+/+-HFD: 38.3± 0.2°C; Cry1−/−-HFD:
38.0± 0.2°C).
Body weight
Body weight was not significantly different between mutant
mice and WT animals when the feeding trials started
(Cry1+/+= 25.6± 0.6 g; Cry1−/−= 24.6± 0.4 g). When main-
tained on a STD for 16 weeks, body weight changes did not differ
significantly between Cry1+/+ and Cry1−/− mice (Figure 1A).
After 16 weeks on the HFD, Cry1−/− mice showed a signifi-
cantly lower body weight (37.2± 1.2 g, P < 0.001) compared with
WT mice (45.3± 3.6 g). This effect reached statistical significance
from week 8 [three-way ANOVA: F(15, 225)= 3.09, P < 0.001].
The total weight gain during the feeding period (Figure 2A)
for Cry1−/− mice on HFD was 12.2 g (+52%), whereas the WT
mice on HFD gained 18.7 g (+70%) [three-way ANOVA: F(14,
210)= 2.43, P < 0.01].
Food intake
Analysis of food intake of animals on HFD shows that both WT
and Cry1−/− mice had similar mean energy intake ranging from
13.0± 0.4–16.7± 0.5 to 11.7± 0.7–16.1± 0.6 kcal/day (data not
shown).
Body composition
Analysis of body content showed that Cry1−/− had reduced fat
mass compared to WT animals (−61%) at the end of the 16-week
HFD regimen [F(1, 7)= 12.34, P < 0.001], while they had simi-
lar lean mass accounting to 17.1± 0.2% (WT) and 18.8± 1.0%
(Cry1−/−) of total body mass (Figure 3).
Lipid and glucose profiles
Because changes in weight are often associated with shifts in
glucose and lipid metabolism, we surveyed serum levels of
glucose, TGs, and FFAs. Tests were performed on mice that
were maintained on HFD diet. Results revealed no difference
in any of these parameters between WT and Cry1−/− mice
(Table 1).
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FIGURE 1 | Growth curves of WT control, Cry1-, and Cry2-deficient
mice under STD and HFD. Body weight for age-matched controls
(A): Cry1+/+ (filled symbols) and Cry1−/− (open symbols) mice, (B): Cry2+/+
(filled symbols) and Cry2−/− mice (open symbols), determined once a week,
on STD (triangles) and HFD (circles) regimens. Cry1 group: n=5
(Cry1+/+-STD) and 5 (Cry1−/−-STD) and n=4 (Cry1+/+-HFD) and 5
(Cry1−/−-HFD); Cry2 group: n=6 (Cry2+/+-STD) and n=7 (Cry2−/−-STD), and
n=8 (Cry2+/+-HFD) and n=6 (Cry2−/−-STD). *P <0.05, ns P >0.05
indicated for genotype comparison, two-way ANOVA for body weight with
repeated measures on factor week. §P <0.05, one-way ANOVA followed by
Dunnett’s test for comparison with week 1 with repeated measures for
parameter weight. Values shown are mean±SEM.
SUSCEPTIBILITY OF CRY2−/− MICE TO HIGH-FAT-INDUCED OBESITY
Growth and body temperature
Cry2-deficient mice displayed the same fur quality than WT
animals and they grew normally. Naso-anal length was simi-
lar in both groups at 15-week of age (Cry2+/+= 9.1± 0.2 cm;
Cry2−/−= 9.1± 0.1 cm). Neither were significant differences in
the body temperature between the two genotypes observed
(Cry2+/+-STD: 37.2± 0.2°C; Cry2−/−-STD: 37.4± 0.2°C).
FIGURE 2 | Cumulative weight gain as calculated from mean weights
of WT control, Cry1-, and Cry2 -deficient mice under STD and HFD.
(A) Cry1+/+ (filled symbols) and Cry1−/− (open symbols) mice, (B): Cry2+/+
(filled symbols) and Cry2−/− mice (open symbols), determined once a week,
on STD (triangles) and HFD (circles) regimens. Cry1 group: n= 5
(Cry1+/+-STD) and 5 (Cry1−/−-STD) and n=4 (Cry1+/+-HFD) and 5
(Cry1−/−-HFD); Cry2 group: n=6 (Cry2+/+-STD) and n=7 (Cry2−/−-STD), and
n=8 (Cry2+/+-HFD) and n= 6 (Cry2−/−-STD). *P <0.05, ns P >0.05
indicated for genotype comparison, two-way ANOVA for body weight with
repeated measures on factor week. Values shown are mean±SEM.
Body weight
Body weight was not significantly different between mutant
mice and WT animals when the feeding trials started
(Cry2+/+= 23.5± 0.6 g; Cry2−/−= 23.9± 0.8 g). When main-
tained on a STD for 10 weeks, body weight changes did not differ
significantly between Cry2+/+ and Cry2−/− mice (Figure 1B).
After 10 weeks on the HFD, Cry2−/− mice showed similar body
weight changes (34.9± 1.1 g) than WT mice (34.4± 1.8 g). The
total weight gain during the feeding period for Cry2−/− mice on
HFD was 10 g (+39%), whereas the WT mice on HFD gained
10.3 g (+41%) (Figure 2B).
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FIGURE 3 | Body composition (% BW) of WT control and Cry1-deficient
mice. Fat and protein masses (% body weight) for WT control Cry1+/+ (filled
bars) and Cry1−/− (open bars)-deficient mice, determined on a HFD
regimen. Cry1 group: n=4 (Cry1+/+-STD) and 5 (Cry1−/−-STD) and n=8
(Cry1+/+-HFD) and 6 (Cry1−/−-HFD). One-way ANOVA for body composition.
***P < 0.001 significant difference for body composition of each strain.
Values shown are mean±SEM.
Table 1 | Plasma lipids and glycemia in fed WT control and Cry1−/−
mice under HFD.
Serum parameters (concentration) WT Cry1−/−
Triglycerides (mg/dl) 80.7±13.2 97.4±16.1
Free cholesterol (g/l) 2.05±0.06 2.10±0.1
Free fatty acid (mmol/ml) 0.95±0.10 0.83±0.15
Glucose (g/l) 2.00±0.09 1.90±0.10
Values shown are mean±SEM. WT, wild-type; HFD, high-fat diet. Shown are
basal plasma lipids concentration, triglycerides (mg/dl), free cholesterol (g/l), free
fatty acid (mmol/ml), and basal glycemia (g/l) in WT control Cry1+/+ and Cry1−/−
mice, determined at week 16 (n = 4).
Inasmuch as there were no weight change differences between
Cry2+/+ and Cry2−/− under both STD and HFD regimens at
week 10, the experiment was discontinued and no additional
metabolism parameters were assessed in these mice.
DISCUSSION
Our data provide several new insights into the physiological func-
tions of CRY in mice. Utilizing Cry1−/− and Cry2−/− mice, we
demonstrate for the first time that Cry1−/− loss interferes with
HFD-induced obesity, and that the physiological basis of this effect
is not related to reduced energy intake. Both Cry1- and Cry2-
deficient mice show no obvious phenotypical changes when fed
a standard high-carbohydrate diet. The animals grow to WT-like
size with normal body weights.
Male WT mice that consume a HFD achieve a body weight
between 41 (Cry2 group) and 70% (Cry1 group) greater than that
of littermates-fed STD and increased adipose tissue mass. HFD are
frequently used in rodent models, including C57BL/6 mice (20,
21), to cause obesity associated with metabolic disturbances such
as hyperglycemia, hyperinsulinemia, and non-alcoholic fatty liver
disease. These phenotypic impairments grossly mimic abdominal
obesity phenotypes in humans and are linked to the development
of type 2 diabetes (22). In the current study, mice lacking Cry2
did not display any overt phenotypical changes on a HFD. This
was in contrast to Cry1−/− mice fed under the same regimen,
which showed a markedly reduced weight gain and reduced body
fat stores compared with WT counterparts. Significant differences
in body weight development generally arise from differences in
energy intake and/or energy excretion. However, in the current
study, we observed that food intake was not significantly decreased
in Cry1−/− mice under HFD conditions, suggesting increased
energy expenditure. Body composition analysis revealed that Cry1
deficit resulted in reduced fat content, while that of protein was
not affected. Moreover, analysis of serum lipid and glucose profiles
showed no difference between Cry1−/− and WT mice at the end
of the 16-week HFD regimen.
Deficiency of Cry1 and/or Cry2 has been shown to impair
autonomic nervous system activity by increasing sympathetic
neural outflow during the light phase, thus activating brown
adipose tissue and hypermetabolism (23). It can be hypothe-
sized that the increase in energy expenditure and resistance to
HFD observed in the current study in Cry1−/− would be con-
sistent with increased sympathetic activity. Alternatively, it can
be argued that the metabolism profile of Cry1−/− mice may be
the result of increased locomotor activity in these mice. While
this parameter was not assessed here, it is worth mentioning that
several previous studies on Cry1−/− mice reported no difference
in motor behavior between these mutant animals and their WT
counterparts when tested under LD12:12 as was the case in our
study (23, 24).
The metabolism phenotype of Cry1-deficient mice in the
current study contrasts with that recently observed with
Cry1−/−Cry2−/− double mutant mice (18). In this study, mutant
mice were reported to be lean under standard diet and when
challenged with HFD, showed reduced food intake. Despite this
hypophagia, they rapidly gained weight. The authors of this
study suggested that hyperinsulinemia and increased lipid stor-
age might account for the increased vulnerability of this mice to
HFD-induced obesity. The discrepancy in metabolism phenotype
between single and double mutant Cry mice cannot readily be
attributed to methodological differences since the high-fat regi-
men used in both studies was the same (45% KJ fat). Moreover,
background (C57BL/6J) and age range (8- to 10-week-old) of the
mice also did not differ between these studies. It cannot com-
pletely be excluded that this difference is produced by a multitude
of, perhaps small, methodological differences that do not neces-
sarily become clear, even with close scrutiny of published reports.
It is striking that in the Barclay et al.’s (18) study, HFD did not
induce obesity in WT control mice, which is rather surprising
since HFD is frequently used in rodent models, including C57BL/6
mice, to cause obesity associated with metabolic disturbances such
as hyperglycemia, hyperinsulinemia, and non-alcoholic fatty liver
disease (20, 21).
The apparent resistance of Cry1−/− mice to weight gain with
a HFD may seem counterintuitive, since the metabolic conse-
quences of circadian disruption such as those observed in human
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clinical studies in shift workers or in genetic models involving
clock gene ablation are generally associated with increased body
weight and onset of metabolic syndrome (25–30). For example,
mutant mice of the circadian gene Clock overeat become obese
and develop hyperglycemia and dyslipidemia (31). These animals
develop the adipocyte hypertrophy and excessive accumulation of
fat in the liver that are hallmarks of the metabolic syndrome. Dele-
tion of the three circadian period genes in mice cause increased
weight gain on HFD (32). Similarly, Bmal1-deficient mice display
increased fat deposition, elevated TGs/FFA levels, and disrupted
insulin responsiveness (33–37). However, other studies targeting
more selectively the negative arm of the clock have shown that Per1
or Per2 deficiency leads to reduced body weight and fat composi-
tion associated with a decrease in plasma levels of TGs and FFAs.
These changes could not be attributed to differences in food intake
or aberrant circadian regulation, but were suggested to be the result
of increased energy expenditure (16, 17). To explain the metabolic
effects of Per2 ablation in this study, it was demonstrated that this
clock gene modulates peroxisome proliferator-activated receptor
γ2 (PPARγ2), a master regulator of adipogenic differentiation and
lipid metabolism.
It is unclear whether a comparable scenario (i.e., Cry1 control-
ling the activity of proteins critical for adipogenesis by operating
as their natural modulators) can explain the current observed
metabolism profile in Cry1−/− mice. To the best of our knowl-
edge, CRYs have not been described to control lipid metabolism by
regulating transcriptional activity of relevant proteins. However,
they were shown to participate in the regulation of hepatic gluco-
neogenesis notably through CRY-mediated inhibition of cAMP-
mediated phosphorylation of cAMP response element-binding
protein (CREB) (38–40). In particular, it was shown that fasted
Cry1 and Cry2 double KO mice displayed increased expression
of gluconeogenic genes, and blood glucose level in the morning.
Conversely, CRY overexpression resulted in decreased glucose pro-
duction in db/db mice, a mouse model of obesity and diabetes with
excess gluconeogenesis (40). It is difficult to argue that a similar
mechanism may be responsible for the phenotype of Cry1−/−mice
in the current study as their blood glucose levels were not signifi-
cantly different from those of WT animals when fed a HFD. Clearly,
future studies should provide further insight into the underlying
mechanism of the resistance of Cry1−/− mice to weight. It will be
important to determine whether the metabolism profile of Cry1
deficiency is the result of disruption of the circadian regulation of
metabolism and/or involves transcriptional mechanisms by which
Cry regulates metabolic gene expression.
In summary, these results highlight further the importance of
CRY as an important regulator of energy homeostasis by showing
that ablation of Cry1−/−, but not Cry2−/− is associated with rel-
ative resistance to HFD-induced obesity. While our data suggest
that Cry1 may be a potential novel therapeutic target to combat
diet-induced obesity, future studies will be needed to determine if a
pharmacological manipulation of Cry1 also prevents weight gain.
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